M&R Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

M&R Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$313K	Buy	673 +48	+8%	+$23.1K	0.07%	106
2024 Q2	$293K	Buy	625 +100	+19%	+$43.4K	0.07%	106
2024 Q1	$219K	Buy	525 +301	+134%	+$127K	0.05%	123
2023 Q4	$91.1K	Buy	224 +200	+833%	+$73.9K	0.02%	205
2023 Q3	$8.35K	Hold	24	–	–	﹤0.01%	403
2023 Q2	$8.45K	Hold	24	–	–	﹤0.01%	404
2023 Q1	$7.56K	Hold	24	–	–	﹤0.01%	409
2022 Q4	$6.93K	Buy	+24	New	+$7.31K	﹤0.01%	394
2020 Q4	–	Sell	-100	Closed	-$27K	–	470
2020 Q3	$27K	Hold	100	–	–	0.01%	291
2020 Q2	$29K	Hold	100	–	–	0.01%	283
2020 Q1	$23K	Hold	100	–	–	0.01%	295
2019 Q4	$21K	Hold	100	–	–	﹤0.01%	334
2019 Q3	$16K	Hold	100	–	–	﹤0.01%	375
2019 Q2	$18K	Hold	100	–	–	﹤0.01%	367
2019 Q1	$17K	Hold	100	–	–	﹤0.01%	375
2018 Q4	$16K	Hold	100	–	–	﹤0.01%	373
2018 Q3	$19K	Hold	100	–	–	﹤0.01%	381
2018 Q2	$16K	Hold	100	–	–	﹤0.01%	398
2018 Q1	$16K	Hold	100	–	–	﹤0.01%	408
2017 Q4	$14K	Hold	100	–	–	﹤0.01%	420
2017 Q3	$15K	Hold	100	–	–	﹤0.01%	418
2017 Q2	$15K	Hold	100	–	–	﹤0.01%	411
2017 Q1	$10K	Sell	100 -5	-5%	-$440	﹤0.01%	447
2016 Q4	$7K	Hold	105	–	–	﹤0.01%	466
2016 Q3	$9K	Buy	105 +5	+5%	+$473	﹤0.01%	442
2016 Q2	$8K	Buy	+100	New	+$8.64K	﹤0.01%	447

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

M&R Capital Management's VRTX Position: Q3 2024 in Review

M&R Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 7.7% in Q3 2024, buying an estimated $23.1K and bringing the position to 673 shares worth $313K. The position accounts for 0.07% of the portfolio, ranked #106.

M&R Capital Management first reported a position in VRTX in Q2 2016 and has held it in 26 quarters since. 1,545 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

M&R Capital Management held 673 shares of Vertex Pharmaceuticals worth $313K as of Q3 2024.
M&R Capital Management bought 48 Vertex Pharmaceuticals shares in Q3 2024, an estimated $23.1K.
Vertex Pharmaceuticals made up 0.07% of M&R Capital Management's portfolio in Q3 2024, its #106 holding.
M&R Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2016 and has held it in 26 quarters since.
1,545 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on M&R Capital Management's 13F filing for Q3 2024, filed 2 Oct 2024.